Genmab AS logo

Genmab AS(GMAB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
5-STAR RATING
REGULAR BUY
BUY for 95 days
PROFIT SINCE LAST BUY
+80.12% ▲
LAST CLOSE
$51.37
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for GMAB

11/13/2026: GMAB (5-star) is a STRONG-BUY. BUY for 95 days. Simulated Profits (80.12%). Updated daily EoD!

Genmab AS is an international biotechnology company known for developing antibody-based therapeutics through advanced engineering platforms and co-development partnerships. The company's primary business strengths include robust, high-margin royalty streams from blockbusters like DARZALEX and Kesimpta, paired with growing product sales from EPKINLY. Its main growth opportunity lies in expanding its proprietary commercial portfolio and advancing late-stage oncology candidates into earlier treatment lines. However, key risks involve high revenue concentration tied to its main partners, increasing operational expenses, and intense biotechnology competition. Genmab suits growth-oriented healthcare investors who should closely monitor pipeline execution and royalty trends.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitGenmab offers strong top-line revenue growth driven by double-digit royalty increases and expanding proprietary drug sales.
Momentum investorStrong fit while signal remains positivePositive clinical trial readouts and upwardly revised financial guidance can spark sharp near-term upward momentum.
Value investorMixed fitWhile profitable with solid cash flows, its biotech valuation multiples require careful assessment against pipeline execution risks.
Dividend investorWeak fitGenmab does not pay a regular cash dividend, opting instead to reinvest earnings into clinical development and growth.
Low-risk investorWeak fitAs a biotechnology stock subject to clinical trial outcomes, regulatory milestones, and partner concentration, volatility is inevitable.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highBiotech share prices fluctuate significantly based on regulatory decisions, clinical trial results, and broader market sentiment.
Valuation riskMediumInvestors price in high expectations for pipeline assets, leaving little margin for error if commercial milestones miss targets.
Competition risk (biopharmaceutical therapeutic competition)HighIntense rivalry from alternative oncology modalities like CAR-T cell therapies and rival bispecific antibodies threatens long-term market share.
Business qualityStrongGenmab possesses world-class antibody engineering technology platforms and a proven, high-margin royalty business model.
Dividend incomeLow / noneThe company does not distribute regular dividends to common stockholders.
Execution riskMedium / highSuccessfully transitioning from a royalty-dependent model to a self-reliant commercial biopharma enterprise requires flawless operational execution.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 31.67B USD
Price to earnings Ratio 43.91
1Y Target Price 65.1
Price to earnings Ratio 43.91
1Y Target Price 65.1
Volume (30-day avg) 5.9M shares
Beta 0.52
52 Weeks Range 23.62 - 59.97
Updated Date 11/15/2026
52 Weeks Range 23.62 - 59.97
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 1.17

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 74.24%
Avg. Invested days 50
Today’s Advisory Regular Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
GMAB receives a 4-star rating, supported by strong unit economics, solid quantitative characteristics, and solid analyst coverage.

Company Fundamentals

★★★★★
GMAB has moderate overall fundamentals (3 stars), with solid financial health, weak growth momentum, and moderate ownership. In FY2025 versus FY2024, strong cash generation (FCF margin 30.9%) and strong profitability (net margin 25.9%) are partially offset by negative earnings growth (-87.7%), negative revenue growth (-82.7%), very low insider ownership of 0.10%.

Financial Health Rating

★★★★★
GMAB's financial health is supported by strong cash strength, including free-cash-flow generation of $1.1B (30.9% of revenue). Operating efficiency is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
GMAB's growth profile is soft, with the least-weak measure being revenue growth at -82.7% FY2025 versus FY2024. By comparison, while earnings growth (-87.7%, negative) and free-cash-flow growth (-84.8%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 20.9% (moderate) and 95.5% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.10%, which materially reduces the ownership score.

Top 5 Institutional Investors

Paradigm Biocapital Advisors LP 2.13%
Orbis Allan Gray Ltd 1.85%
AllianceBernstein L.P. 1.40%
Deerfield Management Co 1.11%
Deep Track Capital, LP 0.92%

Unit Economics (Per $1K Revenue)

★★★★★
GMAB generates approximately $917 of gross profit, $336 of operating income, and $309 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins and strong cash conversion support the rating, although capital efficiency remains soft.

Economic Dimensions

★★★★★
Effective Tax Rate: 20.02%

Quantitative Style Profile

★★★★★
GMAB has a high-quality, large-cap, liquid, relatively low-volatility profile. Soft valuation is the primary drawback.

Style Classification

Quality Focused

Quality TiltLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Royalty RevenueRoyalties earned from partner-commercialized blockbuster medicines like DARZALEX and Kesimpta.This is Genmab's primary profit engine, providing steady cash flow backed by major global pharma partners.
Net Product Sales and CollaborationsDirect commercial sales and co-promotion profits from proprietary drugs like EPKINLY and Tivdak.Represents Genmab's expanding effort to capture direct product revenues rather than relying solely on partner royalties.
Milestones and ReimbursementsUpfront payments, clinical milestone achievements, and research funding from codevelopment partners.Lump-sum cash inflows that validate pipeline progress and supplement ongoing core operational revenue.

Earnings Date

Report Date 2026-11-05
When Before Market
Estimate 0.36
Actual 0.56

Profitability

Profit Margin 16.97%
Operating Margin (TTM) 30.63%

Management Effectiveness

Return on Assets (TTM) 8.24%
Return on Equity (TTM) 12.07%

Valuation

Trailing PE 43.91
Forward PE 22.17
Enterprise Value 34.76B
Price to Sales(TTM) 7.37
Enterprise Value 34.76B
Price to Sales(TTM) 7.37
Enterprise Value to Revenue 8.09
Enterprise Value to EBITDA 27.63
Shares Outstanding 616.59M
Shares Floating 589.06M
Shares Outstanding 616.59M
Shares Floating 589.06M
Percent Insiders 0.1
Percent Institutions 20.9

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.